CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 477-484

  Weigt, S S ^a   Derhovanessian, A ^a   Liao, E ^b   Hu, S ^a   Gregson, A L ^c   Kubak, B M ^c   Saggar, R ^a   Plachevskiy, V ^a   Fishbein, M C ^d   Lynch III, J P ^a   Ardehali, A ^a   Ross, D J ^a   Wang, H J ^b   Elashoff, R M ^b   Belperio, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Infectious Diseases   (United States)

^d Department of Pathology   (United States)

Author keywords

Chemokines; community acquired respiratory viruses; lung transplantation; rejection; respiratory viral infection

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CORTICOSTEROID; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED RESPIRATORY VIRUS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LUNG GRAFT REJECTION; LUNG LAVAGE; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY VIRUS; VIRAL RESPIRATORY TRACT INFECTION;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CXCR3; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES; VIRUSES;

EID: 84856469808     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03859.x     Document Type: Article

References (20)

1. Christie JD, Edwards LB, Aurora P, et al,. The registry of the International Society for Heart and Lung Transplantation: Twenty-sixth official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28: 1031-1049.
2. Burton CM, Carlsen J, Mortensen J, Andersen CB, Milman N, Iversen M,. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007; 26: 681-686. (Pubitemid 47001706)
3. Khalifah AP, Hachem RR, Chakinala MM, et al,. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170: 181-187. (Pubitemid 38925165)
4. Kumar D, Erdman D, Keshavjee S, et al,. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031-2036. (Pubitemid 41039882)
5. Kumar D, Husain S, Chen MH, et al,. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation; 2010 89: 1028-1033.
6. Kohlmeier JE, Cookenham T, Miller SC, et al,. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol 2009; 183: 4378-4384.
7. Lindell DM, Lane TE, Lukacs NW,. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol 2008; 38: 2168-2179.
8. Wareing MD, Lyon AB, Lu B, Gerard C, Sarawar SR,. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza a virus infection in mice. J Leukoc Biol 2004; 76: 886-895. (Pubitemid 39313726)
9. Belperio JA, Keane MP, Burdick MD, et al,. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169: 1037-1049. (Pubitemid 34753464)
10. Belperio JA, Keane MP, Burdick MD, et al,. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 2003; 171: 4844-4852. (Pubitemid 37310606)
11. Medoff BD, Wain JC, Seung E, et al,. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: Regulation and function. J Immunol 2006; 176: 7087-7095. (Pubitemid 43787890)
12. Weigt SS, Elashoff RM, Huang C, et al,. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903-1911.
13. Cooper JD, Billingham M, Egan T, et al,. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International society for heart and lung transplantation. J Heart Lung Transplant 1993; 12: 713-716. (Pubitemid 23305066)
14. Estenne M, Maurer JR, Boehler A, et al,. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310. (Pubitemid 34224094)
15. Yousem SA, Berry GJ, Cagle PT, et al,. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung rejection study group. J Heart Lung Transplant 1996; 15: 1-15. (Pubitemid 26056119)
16. Stewart S, Fishbein MC, Snell GI, et al,. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242. (Pubitemid 350256994)
17. Weigt SS, Elashoff RM, Keane MP, et al,. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8: 1512-1522. (Pubitemid 351989504)
18. Gottlieb J, Schulz TF, Welte T, et al,. Community-acquired respiratory viral infections in lung transplant recipients: A single season cohort study. Transplantation 2009; 87: 1530-1537.
19. Aksoy MO, Yang Y, Ji R, et al,. CXCR3 surface expression in human airway epithelial cells: Cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L909-918. (Pubitemid 43725053)
20. Milstone AP, Brumble LM, Barnes J, et al,. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28: 131-137. (Pubitemid 44914270)